fda semaglutide update FDA Drug Recalls and Warnings: Illegal GLP-1 Sales and Misleading Marketing by Novo Nordisk and Eli Lilly

Wegovy (Semaglutide) Approved by FDA as a New Dosage Form

27.77

★★★★☆4.8 (126)

FDA Proposes Ban on Bulk Compounding for Semaglutide, Tirzepatide, and Liraglutide

27.14

★★★★★4.9 (98)

🚨 FDA Ends Semaglutide Shortage The FDA has officially declared an end to the shortage of semaglutide, the active ingredient in the popular medications Ozempic and Wegovy. This announcement signals a significant

25.31

★★★★★5.0 (157)

UPDATED: FDA lists all doses of Novo's Wegovy as available, signaling potential end to semaglutide supply rout in US

28.42

★★★★★4.7 (84)

The FDA has removed semaglutide injection products (GLP-1) from the shortage list, ending the temporary rule that allowed pharmacies to compound these medications, often used for weight loss. Compounded drugs are custom-made

24.35

★★★★★4.9 (203)

Hims & Hers stock falls 25% as FDA curtails compounded GLP-1s

24.18

★★★★★5.0 (176)

As of February 21, 2025, the FDA updated its drug shortage list, marking the semaglutide injection shortage as resolved. Semaglutide injections are no longer classified as “currently in shortage,” and both 503A

27.08

★★★★★4.8 (132)